|Author||: Sandro Matosevic|
|Publisher||: Academic Press|
|Release Date||: 2021-01-29|
|ISBN 10||: 9780128206270|
|Pages||: 200 pages|
Breaking Tolerance to Unresponsiveness to Immunotherapy by Natural Killer Cells presents chapters by leaders in translational natural killer cell research and bridges the gap between clinical need and basic science by presenting state-of-the-art knowledge on innate immunity and the challenges associated with translating it to practical adoptive immunotherapies. New approaches, such as the genetic engineering of NK cells and their combination with checkpoint blockade therapies are discussed among other potential interventions to improve natural killer cell functionality against targets. In addition, challenges, such as the difficulty in genetically modifying NK cells or a poor understanding of their effect on checkpoint inhibition are included. The book is a key reference and go-to resource for researchers and clinicians who want to understand the current limitations associated with bringing natural killer cell-based immunotherapies to the clinic. Discusses translational aspects from leaders in the field to facilitate readers' understanding of clinical challenges Addresses important events that occur in patient tumor microenvironments as they pertain to NK cells and how they are, or can be, tackled to overcome immunosuppression of NK cells Focuses on immunometabolism by discussing the metabolic reprogramming that NK cells undergo in solid tumors, including hypoxia, adenosine and other metabolites
|Author||: Jorge Morales-Montor,Mariana Segovia-Mendoza|
|Publisher||: Academic Press|
|Release Date||: 2020-10-14|
|ISBN 10||: 0128220295|
|Pages||: 286 pages|
Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives provides high level knowledge on detailed mechanisms of actions and biological interactions of different immune drugs, with an aim of offering researchers and clinicians cutting-edge therapies to overcome drug resistance. The book explains the latest immunotherapies for different types of cancer, helping users carry out research projects or create alternatives for drug development in the pharmaceutical industry. Topics discussed include the relationship between immunotherapy and macrophages, immune checkpoints in different types of cancer, immune cocktails in solid tumors, and immune-phenotyping. Additionally, the book presents basic and clinical data on immunoresistance and glycosylation. This book is a valuable source for cancer researchers, medical doctors, clinicians and members of the biomedical field who must understand certain mechanisms to fight cancer that is resistant to immunotherapy. Provides basic and clinical evidence based on molecular interactions and clinical studies to address the risks and benefits of cancer immunotherapy Presents the results of new immunotherapy trials, discussing the state-of-the-art in different types of cancer Discusses targeted therapies approved by the FDA, along with therapies with clinical potential used in basic studies
|Publisher||: Academic Press|
|Release Date||: 2019-10-04|
|ISBN 10||: 0128178698|
|Pages||: 376 pages|
Improving the Therapeutic Ratio in Head and Neck Cancer provides a complete review of current approaches to modulating therapeutic sensitivity in head and neck cancer. It presents a broad background of current approaches and by highlighting the potential for clinical translational, introduces a roadmap for how to move promising preclinical findings into the clinic. The book discusses topics such as immunotherapy and molecularly targeted therapies in head and neck cancer, PI3k/mTOR pathway, autophagy inhibition to sensitize HNC to radiation and chemotherapy, TAM and Eph/Ephrin family proteins and metabolic reprogramming to modulate therapeutic sensitivity. Additionally, it details approaches to improve the response to immunotherapy, and Chk1/2 inhibition in radiation and cetuximab resistance. This book is a valuable source to head and neck cancer researchers and advanced students, and to those studying specific approaches in other model systems and disease sites. Provides key scientific background for clinicians when developing novel clinical trials and important examples for basic scientists of the types of work required to move a concept from the lab to the clinic Presents consistent pathway diagrams in each chapter, thus making it easier to understand complicated pathways Includes chapter summaries of the critical next steps needed to move studies from their current state into practice changing clinical data
Leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction. The authors review the mechanisms of immune dysfunction and evasion mechanisms in histologically diverse human tumors, focusing on tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors), that may serve as biomarkers for patient prognosis. They discuss the means by which these immune functions may be protected or restored in order to more effectively support the process of tumor rejection in situ. Cutting-edge techniques are outlined with the capacity to monitor the strength and quality of patients' immune responses using immunocytometry, MHC-peptide tetramers combined with apoptosis assay, ELISPOT assay, and detection of MHC-TAA peptide complexes on tumor cells.
This reference brings together all aspects of renal cell carcinoma, and provides a basis for understanding the disease's origin, progression and responses to immunotherapy.;Examining the current status of cytokine, cell-based and chemotherapeutic methods of treatment, this book: discusses the clinical presentation of advanced renal carcinoma and its therapeutic challenges; reviews prognostic factors and the management of renal cell carcinoma occurring with von Hippel-Landau syndrome; summarizes efforts to identify the tumour suppressor gene deleted from chromosome 3 in most renal cell carcinomas; explicates the role of oncogenes in the progression of renal cell cancer and the molecular correlates of responses to interferon-alpha treatment; details the latest laboratory efforts to establish gene therapy for tumour treatment by transfection of cytokine genes in murine model systems; focuses on biologic response modifier therapy in humans, including cell-mediated immune responses and adoptive immunotherapy; presents preclinical and clinical studies of interleukin-2 alone, in combination with othe cytokines, and with chemothrapeutic agents; and addresses studies on the tumour necrosis factor and low- and high-dose interferon-alpha.
The evidence of cancer in humans, animals and plant species suggests that it is as old as multicellular life on Earth. Why is it so difficult to understand and fight? Because cancer begins from the organism's own mutated single cell focused on its own survival. It would be naive to expect that cancer could be ever entirely eliminated, but there is still hope for finding effective treatments. The book is to give a view of selected aspects of cancer like its spread in nature, novel anticancer drugs based on Chinese herbs or birch bark, novel promising targets of annexins and kinases and progress in immunotherapy. It is our hope that you will find in this book interesting, inspiring and stimulating information concerning cancer research.
Transplantation Immunology Edited by Fritz H. Bach, M.D., and Hugh Auchincloss, Jr., M.D. In recent years, transplantation immunology has evolved as a distinct field founded on the recognition that rejection of a transplanted organ or tissue is mediated by immune mechanisms in the host responding to antigens in the donor tissue. This book provides a comprehensive, up-to-date review of current knowledge regarding the specific immune mechanisms which can cause recipients to reject clinical transplants. The text is divided into four sections: Major and Minor Histocompatibility Antigens, Immunobiology of Graft Rejection, Clinical Transplantation, and Frontiers in Transplantation. The first two sections cover present-day understanding of the genetic controls of immunity as well as the two basic concerns of transplantation immunology, namely donor tissue antigens and the host cellular response. The third section deals with clinical aspects of transplantation, while the fourth looks toward future efforts of scientific research in this field—including advances in tolerance and xenotransplantation. A detailed appendix entitled "Molecular Biology for the Clinician" is included to help make the material accessible to readers of all backgrounds. Authored by a wide range of experts in both clinical and research fields, individual chapters cover such topics as: T cell immunity Antigen presentation Alloreactivity Pancreas and islet cell transplantation Allogeneic bone marrow transplantation Models of tolerance induction Xenotransplantation The swine leukocyte antigen (SLA) complex Transplantation Immunology is an ideal teaching text for the fundamental concepts, latest findings, and future directions in this increasingly important field. This volume will appeal to a wide range of clinicians including surgeons and primary-care physicians, as well as scientists in molecular biology and immunology.
Explore the premier text for immunology at the advanced undergraduate, graduate, and medical school levels. Beginning students appreciate the bookÕs clear writing and informative illustrations, while advanced students and working immunologists value its comprehensive scope and depth. This edition is thoroughly revised and up to date with significant developments in the field, especially on the topic of innate immunity.
This timely book, published just as cancer immunotherapy comes of age, summarizes the rationale, present status, and future perspective for cancer immunotherapy. Included are explanations of the constitution of the immune system and immunocheckpoints, the mechanism of antigen presentation and recognition, valuable modalities, clinical trials and guidance, personalization, and biomarkers, all of which are essential for understanding the success of cancer immunotherapy. This innovative therapy has been investigated worldwide as the fourth line of cancer treatment after the standard treatments of surgery, chemotherapy, and radiotherapy. The progress in fundamental understanding of tumor immunology and the recent advances in clinical trials have opened new avenues with a cancer vaccine in 2010 and immunocheckpoint modulation in 2011, with their approval already granted in the United States. Today, there are no doubts, even among experts in cancer chemotherapy and radiotherapy, that the immune system plays a vital role in tumor eradication. Following American approval, many clinical trials of cancer immunotherapy are being conducted. With this book the reader will readily understand the paradigm shift in cancer treatment and will realize the importance of cancer immunotherapy. The great value of immunotherapy will be obvious, not only for tumor shrinkage but for prolonging patient survival.